Associate Professor Gal Markel, MD PhD
Dr. Markel is a medical oncologist, an associate professor at Sackler Faculty of Medicine at Tel Aviv University and the Chief Scientist of the Ella Lemelbaum Institute of Immuno-Oncology at Sheba Medical Center. He completed his PhD in Immunology in 2004 with highest honors, and his MD at 2005, both at the Hebrew University of Jerusalem, Israel.
Gal Markel is an internationally recognized expert in translational tumor immunology and clinical immuno-oncology. He is the author of 85 peer-reviewed papers and the inventor of more than 20 patents. He was the scientific founder and Chief Scientific Officer of cCAM Biotherapeutics, which identified CEACAM1 as an immune checkpoint and was acquired by Merck & Co in July 2015. Gal is a highly active speaker and has given numerous international talks, including TED MED, and has won many awards, such as from the Israel Cancer Association and the Wolf foundation.
Gal serves on the steering committee of the Israel Society for Cancer Research, and is a member of ASCO, AACR, EACR, AAI and Israel Society for Clinical Oncology and Radiotherapy.